On April 14, Jianfeng Group released its 2025 annual report. In 2025, the Company achieved an operating income of RMB 2.568 billion, with a year-on-year decrease of 10.74%; the net profit attributable to the parent company reached RMB 412 million, with a year-on-year increase of 281.43%. The company intends to distribute a cash dividend of 1.00 yuan (including tax) per 10 shares to all shareholders, totaling about 41.0974 million yuan. During the reporting period, the amount of shares repurchased by the company through centralized bidding was about 19.997 million yuan. The total amount of cash dividends and repurchases was about 61.0945 million yuan, accounting for 14.83% of the net profit attributable to the parent company. During the
reporting period, Jianfeng Group's cement-based building materials business realized revenue of 1.197 billion yuan, down 10.87% from the same period last year, with gross interest rate of 21.80%. The annual cement sales volume was 5.2736 million tons, which was the same as that of the previous year. The company deeply practices the concept of green development, and promotes cost reduction and efficiency enhancement through the use of alternative fuels, photovoltaic power generation and energy-saving and consumption-reducing transformation. During the
reporting period, Jianfeng Group's pharmaceutical business realized revenue of 835 million yuan, down 11.42% from the same period last year, and gross interest rate was 19.78%. Affected by the price reduction and the rising cost of raw materials, the gross profit margin of the company's core products such as anti-infection, cardiovascular and cerebrovascular declined. The company is accelerating the integrated layout of the whole industry chain from intermediates, APIs to preparations to cope with the impact of industry changes. During the
reporting period, despite the overall performance pressure, the company still insisted on R & D transformation. In 2025, the total R & D investment was 96.7238 million yuan, of which the capitalized R & D investment accounted for about 8.89%. The company continued to promote the research and development of anti-infective drugs, cardiovascular and cerebrovascular drugs, antidepressant drugs and ophthalmic drugs, focusing on the two major areas of anti-cancer drugs, geriatric and infant drugs. In 2025, Jianfeng Pharmaceutical and its subsidiaries obtained the marketing approval of roxastat capsules, and four bulk drugs including roxastat, engliflozin, terdizolamide phosphate and voronoxan fumarate were approved for marketing; JFAN-1001 methanesulfonate capsules were approved for clinical drug combination trials; and domestic and foreign registration applications for several products were completed.
Looking forward to 2026, the working principle of Jianfeng Group is to strengthen market orientation, innovate mechanisms and methods, and cultivate competitive advantages. The overall goal is: by the end of 2026, the total assets will increase by 5%, the net assets will increase by 2%, the sales revenue will be 2.8 billion yuan, the project construction will be safe, fast and orderly, and the environmental emission indicators will be fully up to the standard.
浙公网安备33010802003254号